REFERENCES
1. Dianov GL, Hubscher U. Mammalian base excision repair: the forgotten archangel. Nucleic Acids Res 2013;41:3483-90.
2. Wilson DM, Bohr VA. The mechanics of base excision repair, and its relationship to aging and disease. DNA repair 2007;6:544-59.
3. Demple B, Harrison L. Repair of oxidative damage to DNA: enzymology and biology. Annu Rev Biochem 1994;63:915-48.
4. Hegde ML, Hazra TK, Mitra S. Early steps in the DNA base excision/single-strand interruption repair pathway in mammalian cells. Cell Res 2008;18:27-47.
5. Weinfeld M, Mani RS, Abdou I, Aceytuno RD, Glover JN. Tidying up loose ends: the role of polynucleotide kinase/phosphatase in DNA strand break repair. Trends Biochem Sci 2011;36:262-71.
6. Demple B, Sung JS. Molecular and biological roles of Ape1 protein in mammalian base excision repair. DNA Repair (Amst) 2005;4:1442-9.
7. Wiederhold L, Leppard JB, Kedar P, Karimi-Busheri F, Rasouli-Nia A, Weinfeld M, Tomkinson AE, Izumi T, Prasad R, Wilson SH, Mitra S, Hazra TK. AP endonuclease-independent DNA base excision repair in human cells. Mol Cell 2004;15:209-20.
8. Allinson SL, Dianova, II, Dianov GL. DNA polymerase beta is the major dRP lyase involved in repair of oxidative base lesions in DNA by mammalian cell extracts. EMBO J 2001;20:6919-26.
9. Horton JK, Prasad R, Hou E, Wilson SH. Protection against methylation-induced cytotoxicity by DNA polymerase beta-dependent long patch base excision repair. J Biol Chem 2000;275:2211-8.
10. Sobol RW, Watson DE, Nakamura J, Yakes FM, Hou E, Horton JK, Ladapo J, Van Houten B, Swenberg JA, Tindall KR, Samson LD, Wilson SH. Mutations associated with base excision repair deficiency and methylation-induced genotoxic stress. Proc Natl Acad Sci USA 2002;99:6860-5.
11. Kunkel TA, Alexander PS. The base substitution fidelity of eucaryotic DNA polymerases. Mispairing frequencies, site preferences, insertion preferences, and base substitution by dislocation. J Biol Chem 1986;261:160-6.
12. Lindahl T, Barnes DE. Repair of endogenous DNA damage. Cold Spring Harb Symp Quant Biol 2000;65:127-33.
13. Friedberg EC, Walker GC, Siede W. DNA Repair and Mutagenesis. Washington, DC: ASM Press; 2006. Available from: https://onlinelibrary.wiley.com/doi/book/10.1128/9781555816704 [Last accessed on 6 Jun 2022].
14. Starcevic D, Dalal S, Sweasy JB. Is there a link between DNA polymerase beta and cancer? Cell Cycle 2004;3:998-1001. Available from: https://www.tandfonline.com/doi/abs/10.4161/cc.3.8.1062 [Last accessed on 6 Jun 2022]
15. Lang T, Maitra M, Starcevic D, Li SX, Sweasy JB. A DNA polymerase beta mutant from colon cancer cells induces mutations. Proc Natl Acad Sci USA 2004;101:6074-9.
16. Sweasy JB, Lang T, Starcevic D, Sun KW, Lai CC, Dimaio D, Dalal S. Expression of DNA polymerase {beta} cancer-associated variants in mouse cells results in cellular transformation. Proc Natl Acad Sci USA 2005;102:14350-5.
17. Al-Tassan N, Chmiel NH, Maynard J, et al. Inherited variants of MYH associated with somatic G:C-->T:a mutations in colorectal tumors. Nat Genet 2002;30:227-32.
18. Banda DM, Nunez NN, Burnside MA, Bradshaw KM, David SS. Repair of 8-oxoG:a mismatches by the MUTYH glycosylase: mechanism, metals and medicine. Free Radic Biol Med 2017;107:202-15.
19. Cheadle JP, Sampson JR. MUTYH-associated polyposis--from defect in base excision repair to clinical genetic testing. DNA Repair (Amst) 2007;6:274-9.
20. Sampson JR, Dolwani S, Jones S, et al. Autosomal recessive colorectal adenomatous polyposis due to inherited mutations of MYH. The Lancet 2003;362:39-41.
21. Nielsen M, Morreau H, Vasen HF, Hes FJ. MUTYH-associated polyposis (MAP). Crit Rev Oncol Hematol 2011;79:1-16.
22. Chow E, Thirlwell C, Macrae F, Lipton L. Colorectal cancer and inherited mutations in base-excision repair. Lancet Oncol 2004;5:600-6.
23. Hutchcraft ML, Gallion HH, Kolesar JM. MUTYH as an emerging predictive biomarker in ovarian cancer. Diagnostics (Basel) 2021;11:84.
24. Weren RD, Ligtenberg MJ, Kets CM, et al. A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer. Nat Genet 2015;47:668-71.
25. Weren RD, Ligtenberg MJ, Geurts van Kessel A, De Voer RM, Hoogerbrugge N, Kuiper RP. NTHL1 and MUTYH polyposis syndromes: two sides of the same coin? J Pathol 2018;244:135-42.
26. Das L, Quintana VG, Sweasy JB. NTHL1 in genomic integrity, aging and cancer. DNA Repair (Amst) 2020;93:102920.
27. Dizdaroglu M. Base-excision repair of oxidative DNA damage by DNA glycosylases. Mutat Res 2005;591:45-59.
28. Díaz-Gay M, Alexandrov LB. Unraveling the genomic landscape of colorectal cancer through mutational signatures. Adv Cancer Res 2021;151:385-424.
29. Slaga TJ, Fischer SM, Nelson K, Gleason GL. Studies on the mechanism of skin tumor promotion: evidence for several stages in promotion. Proc Natl Acad Sci USA 1980;77:3659-63.
30. Land H, Parada LF, Weinberg RA. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 1983;304:596-602.
31. Murray MJ, Shilo BZ, Shih C, Cowing D, Hsu HW, Weinberg RA. Three different human tumor cell lines contain different oncogenes. Cell 1981;25:355-61.
32. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 2011;11:761-74.
33. Lim JKM, Leprivier G. The impact of oncogenic RAS on redox balance and implications for cancer development. Cell Death Dis 2019;10:955.
34. Sarkisian CJ, Keister BA, Stairs DB, Boxer RB, Moody SE, Chodosh LA. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol 2007;9:493-505.
35. Sinn E, Muller W, Pattengale PK, Tepler I, Wallace R, Leder P. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell 1987;49:465-75.
36. Kelekar A, Cole MD. Tumorigenicity of fibroblast lines expressing the adenovirus E1a, cellular p53, or normal c-myc genes. Mol Cell Biol 1986;6:7-14.
37. Jochemsen AG, de Wit CM, Bos JL, van der Eb AJ. Transforming properties of a 15-kDa truncated Ad12 E1A gene product. Virology 1986;152:375-83.
38. Asselin C, Bastin M. Sequences from polyomavirus and simian virus 40 large T genes capable of immortalizing primary rat embryo fibroblasts. J Virol 1985;56:958-68.
39. Levine AJ. The p53 tumor suppressor gene and gene product. Princess Takamatsu Symp 1989;20:221-30.
40. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009;136:823-37.
41. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002;99:3530-9.
42. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002;99:1928-37.
43. Irani K, Xia Y, Zweier JL, et al. Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science 1997;275:1649-52.
44. Bessler WK, Hudson FZ, Zhang H, et al. Neurofibromin is a novel regulator of Ras-induced reactive oxygen species production in mice and humans. Free Radic Biol Med 2016;97:212-22.
45. Huo YY, Li G, Duan RF, et al. PTEN deletion leads to deregulation of antioxidants and increased oxidative damage in mouse embryonic fibroblasts. Free Radic Biol Med 2008;44:1578-91.
46. Mailloux RJ, Gardiner D, O'Brien M. 2-Oxoglutarate dehydrogenase is a more significant source of O2(·-)/H2O2 than pyruvate dehydrogenase in cardiac and liver tissue. Free Radic Biol Med 2016;97:501-12.
47. Ilic N, Birsoy K, Aguirre AJ, et al. PIK3CA mutant tumors depend on oxoglutarate dehydrogenase. Proc Natl Acad Sci USA 2017;114:E3434-e43. 10.1073/pnas.1617922114.
48. Jagadeeswaran R, Jagadeeswaran S, Bindokas VP, Salgia R. Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells. Am J Physiol Lung Cell Mol Physiol 2007;292:L1488-94.
49. Koptyra M, Falinski R, Nowicki MO, et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 2006;108:319-27.
50. Kim JH, Chu SC, Gramlich JL, et al. Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood 2005;105:1717-23.
51. Koundouros N, Poulogiannis G. Phosphoinositide 3-Kinase/Akt signaling and redox metabolism in cancer. Front Oncol 2018;8:160.
52. Mitsushita J, Lambeth JD, Kamata T. The superoxide-generating oxidase Nox1 is functionally required for Ras oncogene transformation. Cancer Res 2004;64:3580-5.
53. Weyemi U, Lagente-Chevallier O, Boufraqech M, et al. ROS-generating NADPH oxidase NOX4 is a critical mediator in oncogenic H-Ras-induced DNA damage and subsequent senescence. Oncogene 2012;31:1117-29.
54. Park MT, Kim MJ, Suh Y, et al. Novel signaling axis for ROS generation during K-Ras-induced cellular transformation. Cell Death Differ 2014;21:1185-97.
55. Ogrunc M, Di Micco R, Liontos M, et al. Oncogene-induced reactive oxygen species fuel hyperproliferation and DNA damage response activation. Cell Death Differ 2014;21:998-1012.
56. Maciag A, Sithanandam G, Anderson LM. Mutant K-rasV12 increases COX-2, peroxides and DNA damage in lung cells. Carcinogenesis 2004;25:2231-7.
57. Kopnin PB, Agapova LS, Kopnin BP, Chumakov PM. Repression of sestrin family genes contributes to oncogenic Ras-induced reactive oxygen species up-regulation and genetic instability. Cancer Res 2007;67:4671-8.
58. Weinberg F, Hamanaka R, Wheaton WW, et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci USA 2010;107:8788-93.
59. Liou GY, Doppler H, DelGiorno KE, et al. Mutant KRas-Induced mitochondrial oxidative stress in acinar cells upregulates EGFR Signaling to drive formation of pancreatic precancerous lesions. Cell Rep 2016;14:2325-36.
60. Budanov AV, Sablina AA, Feinstein E, Koonin EV, Chumakov PM. Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. Science 2004;304:596-600.
61. Lee AC, Fenster BE, Ito H, et al. Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species. J Biol Chem 1999;274:7936-40.
62. Collado M, Gil J, Efeyan A, et al. Tumour biology: senescence in premalignant tumours. Nature 2005;436:642.
63. Dankort D, Filenova E, Collado M, et al. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev 2007;21:379-84.
64. Bartkova J, Rezaei N, Liontos M, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006;444:633-7.
65. Fujita K, Mondal AM, Horikawa I, et al. p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nat Cell Biol 2009;11:1135-42.
66. Kuilman T, Michaloglou C, Vredeveld LC, et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 2008;133:1019-31.
67. Michaloglou C, Vredeveld LC, Soengas MS, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005;436:720-4.
68. Courtois-Cox S, Genther Williams SM, Reczek EE, et al. A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 2006;10:459-72.
70. Moon DO, Kim BY, Jang JH, et al. K-RAS transformation in prostate epithelial cell overcomes H2O2-induced apoptosis via upregulation of gamma-glutamyltransferase-2. Toxicol In Vitro 2012;26:429-34.
71. Recktenwald CV, Kellner R, Lichtenfels R, Seliger B. Altered detoxification status and increased resistance to oxidative stress by K-ras transformation. Cancer Res 2008;68:10086-93.
72. Young TW, Mei FC, Yang G, et al. Activation of antioxidant pathways in ras-mediated oncogenic transformation of human surface ovarian epithelial cells revealed by functional proteomics and mass spectrometry. Cancer Res 2004;64:4577-84.
73. Jeon SM, Chandel NS, Hay N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 2012;485:661-5.
74. Kerr EM, Gaude E, Turrell FK, Frezza C, Martins CP. Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities. Nature 2016;531:110-3.
75. Lim JKM, Delaidelli A, Minaker SW, et al. Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance. Proc Natl Acad Sci USA 2019;116:9433-42.
76. Son J, Lyssiotis CA, Ying H, et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 2013;496:101-5.
77. Venugopal R, Jaiswal AK. Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes. Oncogene 1998;17:3145-56.
78. Itoh K, Wakabayashi N, Katoh Y, et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 1999;13:76-86.
79. Shibata T, Ohta T, Tong KI, et al. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci USA 2008;105:13568-73.
80. Ohta T, Iijima K, Miyamoto M, et al. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res 2008;68:1303-9.
81. Nioi P, Nguyen T. A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity. Biochem Biophys Res Commun 2007;362:816-21.
82. Singh A, Misra V, Thimmulappa RK, et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med 2006;3:e420.
83. Padmanabhan B, Tong KI, Ohta T, et al. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol Cell 2006;21:689-700.
84. Hayes JD, McMahon M. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci 2009;34:176-88.
85. DeNicola GM, Karreth FA, Humpton TJ, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011;475:106-9.
86. Srivastava DK, Husain I, Arteaga CL, Wilson SH. DNA polymerase beta expression differences in selected human tumors and cell lines. Carcinogenesis 1999;20:1049-54.
87. Albertella MR, Lau A, O'Connor MJ. The overexpression of specialized DNA polymerases in cancer. DNA Repair (Amst) 2005;4:583-93.
88. Canitrot Y, Laurent G, Astarie-Dequeker C, et al. Enhanced expression and activity of DNA polymerase beta in chronic myelogenous leukemia. Anticancer Res 2006;26:523-5.
89. Moore DH, Michael H, Tritt R, Parsons SH, Kelley MR. Alterations in the expression of the DNA repair/redox enzyme APE/ref-1 in epithelial ovarian cancers. Clin Cancer Res 2000;6:602-9.
90. Kelley MR, Cheng L, Foster R, et al. Elevated and altered expression of the multifunctional DNA base excision repair and redox enzyme Ape1/ref-1 in prostate cancer. Clin Cancer Res 2001;7:824-30.
91. Bobola MS, Blank A, Berger MS, Stevens BA, Silber JR. Apurinic/apyrimidinic endonuclease activity is elevated in human adult gliomas. Clin Cancer Res 2001;7:3510-8.
92. Wang D, Luo M, Kelley MR. Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition. Mol Cancer Ther 2004;3:679-86.
93. Santana T, Sa MC, de Moura Santos E, et al. DNA base excision repair proteins APE-1 and XRCC-1 are overexpressed in oral tongue squamous cell carcinoma. J Oral Pathol Med 2017;46:496-503.
94. Sato M, Girard L, Sekine I, et al. Increased expression and no mutation of the Flap endonuclease (FEN1) gene in human lung cancer. Oncogene 2003;22:7243-6.
95. Iacobuzio-Donahue CA, Maitra A, Olsen M, et al. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol 2003;162:1151-62.
96. Krause A, Combaret V, Iacono I, et al. Genome-wide analysis of gene expression in neuroblastomas detected by mass screening. Cancer Lett 2005;225:111-20.
97. Kim JM, Sohn HY, Yoon SY, et al. Identification of gastric cancer-related genes using a cDNA microarray containing novel expressed sequence tags expressed in gastric cancer cells. Clin Cancer Res 2005;11:473-82.
98. LaTulippe E, Satagopan J, Smith A, et al. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 2002;62:4499-506.
99. Luo J, Emanuele MJ, Li D, et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009;137:835-48.
100. Ramdzan ZM, Vadnais C, Pal R, et al. RAS transformation requires CUX1-dependent repair of oxidative DNA damage. PLoS Biology 2014;12:e1001807.
101. Kaur S, Ramdzan ZM, Guiot MC, et al. CUX1 stimulates APE1 enzymatic activity and increases the resistance of glioblastoma cells to the Mono-Alkylating agent, temozolomide. Neuro Oncol 2018;20:484-93.
102. Ramdzan ZM, Vickridge E, Li L, et al. CUT domains stimulate pol beta enzymatic activities to accelerate completion of base excision repair. J Mol Biol 2021;433:166806.
103. Wang T, Birsoy K, Hughes NW, et al. Identification and characterization of essential genes in the human genome. Science 2015;350:1096-101.
104. Ellis T, Gambardella L, Horcher M, et al. The transcriptional repressor CDP (Cutl1) is essential for epithelial cell differentiation of the lung and the hair follicle. Genes Dev 2001;15:2307-19.
105. Sinclair AM, Lee JA, Goldstein A, et al. Lymphoid apoptosis and myeloid hyperplasia in CCAAT displacement protein mutant mice. Blood 2001;98:3658-67.
106. Luong MX, van der Meijden CM, Xing D, et al. Genetic ablation of the CDP/Cux protein C terminus results in hair cycle defects and reduced male fertility. Mol Cell Biol 2002;22:1424-37.
107. Ramdzan ZM, Pal R, Kaur S, et al. The function of CUX1 in oxidative DNA damage repair is needed to prevent premature senescence of mouse embryo fibroblasts. Oncotarget 2015;6:3613-26.
108. Network TCGA. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330-7.
109. Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8.
110. Michl P, Ramjaun AR, Pardo OE, et al. CUTL1 is a target of TGF(beta) signaling that enhances cancer cell motility and invasiveness. Cancer Cell 2005;7:521-32.
111. Ripka S, Konig A, Buchholz M, et al. WNT5A--target of CUTL1 and potent modulator of tumor cell migration and invasion in pancreatic cancer. Carcinogenesis 2007;28:1178-87.
112. Ripka S, Neesse A, Riedel J, et al. CUX1: target of Akt signalling and mediator of resistance to apoptosis in pancreatic cancer. Gut 2010;59:1101-10.
113. Ramdzan ZM, Ginjala V, Pinder JB, et al. The DNA repair function of CUX1 contributes to radioresistance. Oncotarget 2017;8:19021-38.
114. Cubelos B, Sebastian-Serrano A, Beccari L, et al. Cux1 and Cux2 regulate dendritic branching, spine morphology, and synapses of the upper layer neurons of the cortex. Neuron 2010;66:523-35.
115. Yamada M, Clark J, McClelland C, et al. Cux2 activity defines a subpopulation of perinatal neurogenic progenitors in the hippocampus. Hippocampus 2015;25:253-67.
116. Iulianella A, Sharma M, Vanden Heuvel GB, Trainor PA. Cux2 functions downstream of Notch signaling to regulate dorsal interneuron formation in the spinal cord. Development (Suppl) 2009;136:2329-34.
117. Conforto TL, Zhang Y, Sherman J, Waxman DJ. Impact of Cux2 on the female mouse liver transcriptome: activation of female-biased genes and repression of male-biased genes. Mol Cell Biol 2012;32:4611-27.
118. Quaggin SE, Vandenheuvel GB, Golden K, Bodmer R, Igarashi P. Primary structure, neural-specific expression, and chromosomal localization of Cux-2, a second murine homeobox gene related to drosophila cut. J Biol Chem 1996;271:22624-34.
119. Kohwi-Shigematsu T, Poterlowicz K, Ordinario E, et al. Genome organizing function of SATB1 in tumor progression. Semin Cancer Biol 2013;23:72-9.
120. Cai S, Han HJ, Kohwi-Shigematsu T. Tissue-specific nuclear architecture and gene expression regulated by SATB1. Nat Genet 2003;34:42-51.
121. Yasui D, Miyano M, Cai S, Varga-Weisz P, Kohwi-Shigematsu T. SATB1 targets chromatin remodelling to regulate genes over long distances. Nature 2002;419:641-5.
122. Han H-J, Russo J, Kohwi Y, Kohwi-Shigematsu T. SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature 2008;452:187-93.
123. Chen H, Takahara M, Oba J, et al. Clinicopathologic and prognostic significance of SATB1 in cutaneous malignant melanoma. J Dermatol Sci 2011;64:39-44.
124. Cheng C, Lu X, Wang G, et al. Expression of SATB1 and heparanase in gastric cancer and its relationship to clinicopathologic features: SATB1 and heparanase in gastric cancer. APMIS 2010;118:855-63.
125. Mir R, Pradhan SJ, Patil P, Mulherkar R, Galande S. Wnt/beta-catenin signaling regulated SATB1 promotes colorectal cancer tumorigenesis and progression. Oncogene 2016;35:1679-91.
126. Pal R, Ramdzan ZM, Kaur S, et al. CUX2 functions as an accessory factor in the repair of oxidative DNA damage. J Biol Chem 2015;290:22520-31.
127. Kaur S, Coulombe Y, Ramdzan ZM, et al. Special AT-rich sequence-binding protein 1 (SATB1) functions as an accessory factor in base excision repair. J Biol Chem 2016;291:22769-80.
128. Marcotte R, Brown KR, Suarez F, et al. Essential gene profiles in breast, pancreatic, and ovarian cancer cells. Cancer discov 2012;2:172-89.
129. Das S, Chattopadhyay R, Bhakat KK, et al. Stimulation of NEIL2-mediated oxidized base excision repair via YB-1 interaction during oxidative stress. J Biol Chem 2007;282:28474-84.
130. Hegde ML, Banerjee S, Hegde PM, et al. Enhancement of NEIL1 protein-initiated oxidized DNA base excision repair by heterogeneous nuclear ribonucleoprotein U (hnRNP-U) via direct interaction. J Biol Chem 2012;287:34202-11.
131. Prasad R, Liu Y, Deterding LJ, et al. HMGB1 is a cofactor in mammalian base excision repair. Mol Cell 2007;27:829-41.
132. Charles Richard JL, Shukla MS, Menoni H, et al. FACT assists base excision repair by boosting the remodeling activity of RSC. PLoS Genet 2016;12:e1006221.
133. Zhou J, Ahn J, Wilson SH, Prives C. A role for p53 in base excision repair. EMBO J 2001;20:914-23.
134. Illuzzi JL, Wilson DM, 3rd. Base excision repair: contribution to tumorigenesis and target in anticancer treatment paradigms. Curr Med Chem 2012;19:3922-36.
135. Canitrot Y, Cazaux C, Frechet M, et al. Overexpression of DNA polymerase beta in cell results in a mutator phenotype and a decreased sensitivity to anticancer drugs. Proc Natl Acad Sci USA 1998;95:12586-90.
136. Tan X, Wang H, Luo G, et al. Clinical significance of a point mutation in DNA polymerase beta (POLB) gene in gastric cancer. Int J Biol Sci 2015;11:144-55.
137. Tang JB, Svilar D, Trivedi RN, et al. N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide. Neuro Oncol 2011;13:471-86.
138. Trivedi RN, Almeida KH, Fornsaglio JL, Schamus S, Sobol RW. The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. Cancer Res 2005;65:6394-400.
139. Trivedi RN, Wang XH, Jelezcova E, et al. Human methyl purine DNA glycosylase and DNA polymerase beta expression collectively predict sensitivity to temozolomide. Mol Pharmacol 2008;74:505-16.
140. Jaiswal AS, Banerjee S, Panda H, et al. A novel inhibitor of DNA polymerase beta enhances the ability of temozolomide to impair the growth of colon cancer cells. Mol Cancer Res 2009;7:1973-83.
141. Jaiswal AS, Panda H, Law BK, et al. NSC666715 and its analogs inhibit strand-displacement activity of DNA polymerase beta and potentiate temozolomide-induced DNA damage, senescence and apoptosis in colorectal cancer cells. PLoS One 2015;10:e0123808.
142. Sobol RW, Horton JK, Kuhn R, et al. Requirement of mammalian DNA polymerase-beta in base-excision repair. Nature 1996;379:183-6.
143. Arian D, Hedayati M, Zhou H, et al. Irreversible inhibition of DNA polymerase beta by small-molecule mimics of a DNA lesion. J Am Chem Soc 2014;136:3176-83.
144. Jelezcova E, Trivedi RN, Wang XH, et al. Parp1 activation in mouse embryonic fibroblasts promotes Pol beta-dependent cellular hypersensitivity to alkylation damage. Mutat Res 2010;686:57-67.
145. Horton JK, Wilson SH. Hypersensitivity phenotypes associated with genetic and synthetic inhibitor-induced base excision repair deficiency. DNA Repair (Amst) 2007;6:530-43.
146. Horton JK, Horton JK, Joyce-Gray DF, et al. Hypersensitivity of DNA polymerase beta null mouse fibroblasts reflects accumulation of cytotoxic repair intermediates from site-specific alkyl DNA lesions. DNA Repair 2003;2:27-48.
147. Yang J, Parsons J, Nicolay NH, et al. Cells deficient in the base excision repair protein, DNA polymerase beta, are hypersensitive to oxaliplatin chemotherapy. Oncogene 2010;29:463-8.
148. Horton JK, Srivastava DK, Zmudzka BZ, Wilson SH. Strategic down-regulation of DNA polymerase beta by antisense RNA sensitizes mammalian cells to specific DNA damaging agents. DNA Repair 1995;23:3810-5.
149. Silber JR, Bobola MS, Blank A, et al. The apurinic/apyrimidinic endonuclease activity of Ape1/Ref-1 contributes to human glioma cell resistance to alkylating agents and is elevated by oxidative stress. Clin Cancer Res 2002;8:3008-18.
150. Bobola MS, Emond MJ, Blank A, et al. Apurinic endonuclease activity in adult gliomas and time to tumor progression after alkylating agent-based chemotherapy and after radiotherapy. Clin Cancer Res 2004;10:7875-83.
151. Bobola MS, Finn LS, Ellenbogen RG, et al. Apurinic/apyrimidinic endonuclease activity is associated with response to radiation and chemotherapy in medulloblastoma and primitive neuroectodermal tumors. Clin Cancer Res 2005;11:7405-14.
152. Luo M, Kelley MR. Inhibition of the human apurinic/apyrimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone. Anticancer Res 2004;24:2127-34.
153. McNeill DR, Lam W, DeWeese TL, Cheng YC, Wilson DM 3rd. Impairment of APE1 function enhances cellular sensitivity to clinically relevant alkylators and antimetabolites. Mol Cancer Res 2009;7:897-906.
154. Rai G, Vyjayanti VN, Dorjsuren D, et al. Small molecule inhibitors of the human apurinic/apyrimidinic endonuclease 1 (APE1). In: probe reports from the NIH molecular libraries program. Bethesda (MD);2010.
155. Montaldi AP, Godoy PR, Sakamoto-Hojo ET. APE1/REF-1 down-regulation enhances the cytotoxic effects of temozolomide in a resistant glioblastoma cell line. Mutat Res Genet Toxicol Environ Mutagen 2015;793:19-29.
156. Liu L, Liu L, Taverna P, et al. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents. Clin Cancer Res 1999;5:2908-17.
157. Taverna P, Liu L, Hwang HS, et al. Methoxyamine potentiates DNA single strand breaks and double strand breaks induced by temozolomide in colon cancer cells. Mutat Re ;485:269-81.
158. Liu L, Nakatsuru Y, Gerson SL. Base excision repair as a therapeutic target in colon cancer. Clin Cancer Res 2002;8:2985-91.
159. Larsen E, Gran C, Saether BE, Seeberg E, Klungland A. Proliferation failure and gamma radiation sensitivity of Fen1 null mutant mice at the blastocyst stage. Mol Cell Biol 2003;23:5346-53.
160. Urbanucci A, Sahu B, Seppala J, et al. Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer. Oncogene 2012;31:2153-63.
161. Agnihotri S, Burrell K, Buczkowicz P, et al. ATM regulates 3-methylpurine-DNA glycosylase and promotes therapeutic resistance to alkylating agents. Cancer Discov 2014;4:1198-213.
162. Agnihotri S, Gajadhar AS, Ternamian C, et al. Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. J Clin Invest 2012;122:253-66.
163. Hermens AF, Bentvelzen PA. Influence of the H-ras oncogene on radiation responses of a rat rhabdomyosarcoma cell line. Cancer Res 1992;52:3073-82.
164. Bernhard EJ, Kao G, Cox AD, et al. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. Cancer Res 1996;56:1727-30.
165. McKenna WG, Weiss MC, Bakanauskas VJ, et al. The role of the H-ras oncogene in radiation resistance and metastasis. Int J Radiat Oncol Biol Phys 1990;18:849-59.
166. Miller AC, Kariko K, Myers CE, Clark EP, Samid D. Increased radioresistance of EJras-transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation. Int J Cancer 1993;53:302-7.
